Aurigene and Debiopharm Group™ report nomination of development candidate Debio 0617B in oncology

Aurigene and Debiopharm Group™ report nomination of development candidate Debio 0617B in oncology

Lausanne, Switzerland and Bangalore, India – Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies,  announced the successful nomination of a development candidate, Debio 0617B. The companies signed an exclusive worldwide license agreement, to develop and commercialize Debio 0617B in 2012.

Source: Debiopharm (Link to full release)

About the author

Amitabh Arora

Amitabh Arora

Amitabh Arora has more than 18 years of experience promoting foreign direct investments (FDI), trade and economic relations between India and Switzerland, South Korea, United Kingdom and Canada. He is currently working as Director Key Accounts at the Greater Geneva Berne area (GGBa), the economic development agency of western Switzerland. GGBa offers a comprehensive range of services at no charge to foreign companies seeking to establish a presence in Switzerland. He is also the founder of FDITracker.com, tracking FDI developments worldwide. Amitabh has a Masters in International Business from the Indian Institute of Foreign Trade (IIFT) and a Bachelor of Business Studies (BBS) from College of Business Studies, India.

    Leave a Reply